Bonus Presentations

NON-CME/CE
DAY 1
FRIDAY,
SEPTEMBER 18
7:00 am
—
8:00 am
Non-CME/CE Bonus Presentation
New Treatment Approaches Across Disease Settings for HER2-Expressing Breast Cancer

Speaker: Kit Y. Lu, MD

Sponsored by Daiichi Sankyo, Inc.

A discussion reviewing the latest clinical data and emerging evidence in HER2- expressing breast cancer, presented by Daiichi Sankyo, Inc. and AstraZeneca.

9:45 am
—
10:45 am
Non-CME/CE Bonus Presentation
In ESR1-mutated, ER+/HER2- mBC following progression on ET ORSERDU® (elacestrant): Powerful efficacy in EMERALD@, now with published real-world evidence 1-3

Speaker: Adam Brufsky, MD, PHD, FACP

Sponsored by Menarini Stemline
12:55 pm
—
1:55 pm
Non-CME/CE Bonus Presentation
Learn About a Treatment Option for Patients With HR+/HER2+ mBC

Speaker: Priya Rudolph, MD, PhD

Sponsored by Pfizer
5:10 pm
—
6:10 pm
Non-CME/CE Bonus Presentation
An Overview of VEPPANU (vepdegestrant): The First-and-Only FDA-Approved PROTAC
A PROTAC is a type of heterobifunctional protein degrader, a novel treatment class Internal

Speaker: TBD

Sponsored by Rigel Pharmaceuticals
DAY 2
SATURDAY,
SEPTEMBER 19
7:00 am
—
8:00 am
Non-CME/CE Bonus Presentation
A 2L Treatment Option for HR+/HER2- aBC or mBC with PIK3CA, AKT1, or PTEN Alterations Following Progression on or After ET +/- CDK4/6
A Next-Generation 1L Approach in HR+/HER2- mBC: The Role of Early Intervention Upon Emergence of Endocrine Resistance

Speaker: Kit Lu, MD

Sponsored by AstraZeneca
10:00 am
—
11:00 am
Non-CME/CE Bonus Presentation
Pause Progression: An Emerging Approach Using an Oral ER Antagonist

Speaker: Lauren A. Mauro, MD

Sponsored by Eli Lilly and Company

In this program, you’ll examine the latest data on Inluriyo to discern how and when to utilize it in your practice.

1:15 pm
—
2:15 pm
Non-CME/CE Bonus Presentation
Clinical applications of Cerianna (FES) PET/CT: A case-based perspective

Speaker: Kit Lu, MD

Sponsored by GE Healthcare

(FES) PET is a molecular imaging diagnostic agent which reveals the presence of estrogen receptor and its potential ability to bind to estrogen. Join us for a case-based symposium designed for providers treating breast cancer patients. We'll explore real-world cases through the perspective of a medical oncologist. Learn from a clinical expert how this imaging tool is used in clinical practice, helping to provide clearer diagnoses. Cerianna (FES) PET is reshaping the diagnostic landscape for ER+ recurrent and metastatic breast cancer patients.

DAY 2
SATURDAY,
SEPTEMBER 19
No items found.
Disclaimer: Bonus Presentations are independently organized and not an official part of the Perspectives in Breast Cancer Care 2026 program. All presentations are Non-CME unless otherwise noted.